Peptide group to meet with White House over pending regulatory plan

The American Academy of Peptide Medicine is scheduled to convene with the Office of Management and Budget on Wednesday to deliberate on a forthcoming regulatory proposal. This policy could potentially broaden access to peptides, which are unregulated substances that have gained popularity among wellness influencers.

Robert F. Kennedy Jr., the Health and Human Services Secretary, and the American Academy of Peptide Medicine have expressed concerns regarding these substances. In July, a panel of outside advisors to the FDA, which included individuals with ties to the peptide industry, provisionally suggested adding several peptides to the FDA’s list of compounds that can be synthesized at pharmacies. However, FDA scientists have raised reservations about this recommendation.

The notice issued by the FDA could introduce significant changes, but the specifics of the policy, such as the peptides it would cover and the conditions that the FDA may impose on compounding, remain uncertain at this stage. Scott Brunner, the CEO of the Alliance for Pharmacy Compounding, expressed his perspective, stating that while the notice may be "potentially significant," there is still a lack of clarity regarding the policy's details.